Meet Denver Lough MD, PhDFounder, Chairman, and Chief Executive Officer, PolarityTE, Inc.
Dr. Denver Lough has always sought to investigate reality, pursue complex simplicity and develop a new paradigm in translational science. He left his original career plan behind at the Johns Hopkins Hospital Department of Plastic and Reconstructive Surgery
to provide tangible and pragmatic therapies for patients who were trapped in the trenches of medicine and to improve health outcomes and health economics for patients, providers and payors. He recognizes that the healthcare system is broken and that industry has a responsibility to humanity to continue to develop not only consistently better therapies, but also to deliver them at lower costs and assure access for patients.
Denver is the Chairman and Chief Executive Officer of the NASDAQ traded biotechnology company PolarityTE, Inc. and discoverer of micro-aggregate cell-based technologies for applications in the regeneration of functionally-polarized tissues. Within less than 2 years he has achieved both significant technical and business milestones including bringing PolarityTE public, raising $140M of capital, building a team of 140 employees (77% of whom have graduate degrees) and building out a 400,000 sq. ft. PolarityTE Biomedical Campus throughout Utah. During this time, PolarityTE launched its first commercial product, SkinTE, which impacts and saves patients’ lives suffering from burns, wounds and traumas. PolarityTE has also demonstrated its commitment to contributing to building biotechnology infrastructure in the state by acquiring Utah’s only preclinical contract research organization (CRO), and is developing additional contract laboratory facilities at the headquarters in Salt Lake City. By cultivating the community and system, Denver seeks to help Utah become the nidus of a new era of biotechnology hubs which will contribute to the State’s economy, workforce and even greater attraction to Utah by other innovators.
Dr. Lough has significant experience with bench-to-bedside translational research applications which include tissue regeneration;
intestinal transplantation; hand, face, and penile transplantation and life science product development. He holds a medical degree
(MD) as well as a doctorate (PhD) in Biochemistry, Molecular and Cell Biology from Georgetown University. He has authored
hundreds of publications and book chapters, including scientific journal covers throughout his career in academic science and
medicine, which led to numerous awards and accolades including:
• The Alpha Omega Alpha Medical Honor Society
• The Phi Beta Kappa Academic Honor Society
• Life Science Fellowship Award from AAAS
• Roche Presidential Student Mentor Award
• The Roche Organ Transplantation Research Foundation Award
• The Broad Medical Foundation Life Science Award
• Plastic Surgery Research Council Previous Chairman Snyder Award
• Plastic Surgery Research Council Peter J. Gingrass – Best Science Paper Award
• The Russell Military Scholars Program Award
• The American Society for Reconstructive Microsurgery (ASRM) Award
• Johns Hopkins Annual Research Basic Science Award in Plastic and Reconstructive Surgery
• Georgetown University Medical Center Basic Science Research Award in Medicine and Transplantation
• Georgetown University Medical Center, Biomedical Graduate Research Organization Award in BMCB
• Southern Illinois School of Medicine Basic Science Award
• Memorial Medical Center Foundation Grant
• Plastic Surgery Foundation Grant
In 2015, following the largest civilian mass casualty fire in the world at the Formosa Water in Taiwan, President Ma Ying-Jeou
selected a Johns Hopkins emergency response team, including Dr. Lough, to assist the Taiwanese government and healthcare
system in the evaluation and treatment of over 500 adolescent youth tragically burned in the event (PTE.Cool/JH-ERT). This event
spurred the acceleration of the founding of PolarityTE.